|
21 Companies |
|
32 Products |
|
32 Products |
|
31 Mechanisms of Action |
|
0 Trials |
|
632 News |
|
| «123456789101112» |
- brivaracetam / Generic mfg.
Trial primary completion date: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam (clinicaltrials.gov) - May 4, 2015
P3, N=108, Active, not recruiting, Sponsor: UCB Pharma
Trial primary completion date: Jun 2015 --> Dec 2017
- Trial primary completion date: ANSeR- The Algorithm for Neonatal Seizure Recognition Study (clinicaltrials.gov) - Apr 30, 2015
P=N/A, N=408, Recruiting, Sponsor: University College Cork
Trial primary completion date: Jun 2015 --> Dec 2017 Trial primary completion date: Jul 2014 --> May 2015
- levetiracetam / Generic mfg.
Enrollment change: A Dose-Escalation, Safety and Feasibility Study of Enteral LVT for Seizure Control in Pediatric CM (clinicaltrials.gov) - Apr 30, 2015
P2, N=43, Recruiting, Sponsor: University of Rochester
Trial primary completion date: Jul 2014 --> May 2015 N=60 --> 43
- || Trial primary completion date: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders (clinicaltrials.gov) - Apr 25, 2015
P1/2, N=60, Recruiting, Sponsor: INSYS Therapeutics Inc
N=60 --> 43 Trial primary completion date: Apr 2015 --> Sep 2015
- ||| Enrollment change: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders (clinicaltrials.gov) - Apr 19, 2015
P1/2, N=60, Recruiting, Sponsor: INSYS Therapeutics Inc
Trial primary completion date: Apr 2015 --> Sep 2015 N=24 --> 60
- levetiracetam / Generic mfg.
Trial primary completion date: Seizure Prophylaxis in Aneurysm Repair (clinicaltrials.gov) - Apr 14, 2015
P4, N=266, Recruiting, Sponsor: Indiana University
N=24 --> 60 Trial primary completion date: Dec 2015 --> Dec 2017
- carvedilol controlled-release / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy. (clinicaltrials.gov) - Apr 14, 2015
P2/3, N=6, Terminated, Sponsor: Columbia University
Trial primary completion date: Dec 2015 --> Dec 2017 N=33 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2009 --> Oct 2010; PI left the institution.
- | Fycompa (perampanel) / Eisai, Catalyst Pharma
Trial completion: Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs (clinicaltrials.gov) - Apr 13, 2015
P2, N=41, Completed, Sponsor: Eisai Inc.
N=33 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2009 --> Oct 2010; PI left the institution. Active, not recruiting --> Completed
- Trial completion: Stress Management Intervention for Living With Epilepsy (SMILE) (clinicaltrials.gov) - Apr 8, 2015
P2, N=95, Completed, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy (clinicaltrials.gov) - Apr 7, 2015
P2, N=28, Completed, Sponsor: El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Active, not recruiting --> Completed Recruiting --> Completed | N=45 --> 28
- lacosamide / Generic mfg.
Enrollment open: Lacosamide in Preventing Seizures in Participants With Malignant Glioma (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=302, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed | N=45 --> 28 Active, not recruiting --> Recruiting
- ||||| levetiracetam / Generic mfg., carbamazepine / Generic mfg.
Enrollment closed, Monotherapy: Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures (clinicaltrials.gov) - Mar 31, 2015
P3, N=436, Active, not recruiting, Sponsor: UCB Pharma SA
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- lacosamide / Generic mfg.
Enrollment closed: Lacosamide in Preventing Seizures in Participants With Malignant Glioma (clinicaltrials.gov) - Mar 25, 2015
P=N/A, N=302, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| vigabatrin / Generic mfg.
Enrollment closed: A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) (clinicaltrials.gov) - Mar 18, 2015
P4, N=80, Active, not recruiting, Sponsor: Lundbeck LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Trial completion, Enrollment change, HEOR, Surgery: Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery (clinicaltrials.gov) - Mar 18, 2015
P=N/A, N=82, Completed, Sponsor: Radiation Therapy Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Completed | N=170 --> 82
- | Enrollment open: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders (clinicaltrials.gov) - Mar 17, 2015
P1/2, N=24, Recruiting, Sponsor: INSYS Therapeutics Inc
Recruiting --> Completed | N=170 --> 82 Not yet recruiting --> Recruiting
- Trial primary completion date: Copeptin in Childhood Epilepsy (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=350, Recruiting, Sponsor: University Hospital, Basel, Switzerland
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2014 --> Oct 2015
- ||||| Trial initiation date, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome (clinicaltrials.gov) - Mar 7, 2015
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
Trial primary completion date: Mar 2014 --> Oct 2015 Initiation date: Apr 2015 --> Aug 2015 | Trial primary completion date: Oct 2015 --> Feb 2016
- ||||| Trial initiation date, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder (clinicaltrials.gov) - Mar 7, 2015
P3, N=196, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
Initiation date: Apr 2015 --> Aug 2015 | Trial primary completion date: Oct 2015 --> Feb 2016 Initiation date: Mar 2015 --> Aug 2015 | Trial primary completion date: Apr 2016 --> Sep 2016
- ||||| Trial initiation date, Trial primary completion date: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome (clinicaltrials.gov) - Mar 7, 2015
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
Initiation date: Mar 2015 --> Aug 2015 | Trial primary completion date: Apr 2016 --> Sep 2016 Initiation date: Apr 2015 --> Aug 2015 | Trial primary completion date: Oct 2015 --> Feb 2016
- |||| levetiracetam / Generic mfg.
Trial completion: A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures (clinicaltrials.gov) - Feb 28, 2015
P2, N=87, Completed, Sponsor: UCB Pharma
Initiation date: Apr 2015 --> Aug 2015 | Trial primary completion date: Oct 2015 --> Feb 2016 No longer recruiting --> Completed
- Trial completion, Enrollment change: Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=9, Completed, Sponsor: University of Alabama at Birmingham
No longer recruiting --> Completed Recruiting --> Completed | N=20 --> 9
- |||| everolimus / Generic mfg.
Trial primary completion date: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Feb 27, 2015
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=20 --> 9 Trial primary completion date: May 2016 --> Sep 2016
- || Enrollment change: Prospective Study of Comparison Between the Modified Atkins Diet and Classic Ketogenic Diet for Intractable Childhood Epilepsy (clinicaltrials.gov) - Feb 26, 2015
P=N/A, N=104, Completed, Sponsor: Yonsei University
Trial primary completion date: May 2016 --> Sep 2016 N=78 --> 104
- Trial primary completion date: Exercise Education for Adults With Seizure Disorders (clinicaltrials.gov) - Feb 24, 2015
P0, N=50, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=78 --> 104 Trial primary completion date: Jun 2016 --> Dec 2015
- ||||| topiramate XR / Generic mfg.
Enrollment change: Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures (clinicaltrials.gov) - Feb 23, 2015
P3, N=210, Completed, Sponsor: Upsher-Smith Laboratories
Trial primary completion date: Jun 2016 --> Dec 2015 N=172 --> 210
- |||| Trial primary completion date: Modified Atkins Diet Plus KetoCal for Adult Epilepsy (clinicaltrials.gov) - Feb 19, 2015
P2/3, N=80, Recruiting, Sponsor: Johns Hopkins University
N=172 --> 210 Trial primary completion date: Mar 2016 --> Mar 2017
- Enrollment open: Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1® (clinicaltrials.gov) - Feb 18, 2015
P=N/A, N=20, Recruiting, Sponsor: Coopervision, Inc.
Trial primary completion date: Mar 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- Enrollment closed, Enrollment change, Trial primary completion date, HEOR: Enhancing Physical Activity Levels in Children With Epilepsy (clinicaltrials.gov) - Feb 13, 2015
P=N/A, N=45, Active, not recruiting, Sponsor: Children's Hospital of Eastern Ontario
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=100 --> 45 | Trial primary completion date: Oct 2014 --> Apr 2015
- Enrollment closed: Cardiac Arrhythmias in Epilepsy: the CARELINK-study (clinicaltrials.gov) - Feb 11, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: Stichting Epilepsie Instellingen Nederland
Recruiting --> Active, not recruiting | N=100 --> 45 | Trial primary completion date: Oct 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- Fycompa (perampanel) / Eisai
Enrollment change, Trial withdrawal: To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures (clinicaltrials.gov) - Feb 10, 2015
P4, N=0, Withdrawn, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting N=62 --> 0 | Not yet recruiting --> Withdrawn
- |||| Trial completion: Clinical Performance of Hydrogel vs. Silicone Hydrogel Contact Lenses (clinicaltrials.gov) - Feb 10, 2015
P4, N=60, Completed, Sponsor: Coopervision, Inc.
N=62 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed
- lacosamide / Generic mfg., fosphenytoin / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures (clinicaltrials.gov) - Jan 26, 2015
P2, N=74, Active, not recruiting, Sponsor: Aatif Husain
Recruiting --> Completed Recruiting --> Active, not recruiting | N=200 --> 74 | Trial primary completion date: Sep 2014 --> Jun 2015
- ||||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Enrollment change: A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures (clinicaltrials.gov) - Jan 26, 2015
P3, N=307, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | N=200 --> 74 | Trial primary completion date: Sep 2014 --> Jun 2015 N=165 --> 307
- Enrollment open, Trial primary completion date: EpiCapno: Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask (clinicaltrials.gov) - Jan 18, 2015
P=N/A, N=20, Recruiting, Sponsor: University of Aarhus
N=165 --> 307 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2013 --> Sep 2015
- ||| Trial completion: Acid Suppressing Drug Seizure Epidemiology Study (clinicaltrials.gov) - Jan 15, 2015
P=N/A, N=8500, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2013 --> Sep 2015 Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal, Trial primary completion date, Surgery: Effect of Music Therapy on Cognitive Recovery (clinicaltrials.gov) - Jan 8, 2015
P=N/A, N=0, Withdrawn, Sponsor: Seton Family of Hospitals
Active, not recruiting --> Completed N=60 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2014 --> Sep 2014
- |||| selurampanel (BGG492) / Novartis
Enrollment open, Trial primary completion date: Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 (clinicaltrials.gov) - Jan 8, 2015
P2, N=77, Recruiting, Sponsor: Novartis Pharmaceuticals
N=60 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2014 --> Sep 2014 Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015
- ||||| Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Enrollment closed, Monotherapy: Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures (clinicaltrials.gov) - Jan 8, 2015
P3, N=900, Active, not recruiting, Sponsor: Bial - Portela C S.A.
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Jun 2015 Recruiting --> Active, not recruiting
- || Trial primary completion date: Prospective Research in Infants With Mild Encephalopathy (clinicaltrials.gov) - Jan 6, 2015
P=N/A, N=57, Recruiting, Sponsor: McGill University Health Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2013 --> Dec 2015
- rufinamide / Generic mfg.
New P1 trial: Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects (clinicaltrials.gov) - Jan 6, 2015
P1, N=40, Completed, Sponsor: Wuhan Union Hospital, China
- | New P1/2 trial: Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders (clinicaltrials.gov) - Dec 25, 2014
P1/2, N=24, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
- || Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Trial primary completion date: Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA) (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=300, Recruiting, Sponsor: Bial - Portela C S.A.
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Jun 2014 --> Dec 2015
- || Fycompa (perampanel) / Eisai
Trial primary completion date: To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures (clinicaltrials.gov) - Dec 19, 2014
P4, N=62, Not yet recruiting, Sponsor: Eisai Inc.
Trial primary completion date: Jun 2014 --> Dec 2015 Trial primary completion date: Apr 2016 --> Aug 2016
- |||||||||| New P3 trial: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome (clinicaltrials.gov) - Dec 19, 2014
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
- |||||||||| New P3 trial: Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder (clinicaltrials.gov) - Dec 19, 2014
P3, N=196, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
- |||||||||| New P3 trial: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome (clinicaltrials.gov) - Dec 19, 2014
P3, N=86, Not yet recruiting, Sponsor: INSYS Therapeutics Inc
- phenytoin / Generic mfg., brivaracetam / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures (clinicaltrials.gov) - Dec 17, 2014
P2, N=1, Terminated, Sponsor: UCB BIOSCIENCES, Inc.
N=50 --> 1 | Recruiting --> Terminated | Trial primary completion date: Aug 2016 --> Oct 2014; Termination of study due to low enrollment. There were no safety issues.
- ||||| Plumiaz (diazepam nasal spray) / Acorda
New P2 trial: An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray. (clinicaltrials.gov) - Dec 16, 2014
P2, N=100, Recruiting, Sponsor: Acorda Therapeutics
- lacosamide / Generic mfg.
Trial completion: Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures (clinicaltrials.gov) - Dec 12, 2014
P3, N=9, Completed, Sponsor: UCB Japan Co. Ltd.
There were no safety issues. Recruiting --> Completed